Chartwell Pharmaceuticals
Anusha Ponugoti is a seasoned professional in regulatory affairs with extensive experience in the pharmaceutical industry. Currently serving as a Senior Manager of Regulatory Affairs at Chartwell Pharmaceuticals since March 2023, Anusha has previously held the position of Regulatory Affairs Manager at Contract Pharmacal Corp from April 2018 to December 2022, where responsibilities included developing regulatory submission strategies and coordinating project logistics. Prior experience includes a role as Deputy Manager of Regulatory Affairs at Cipla, where Anusha coordinated regulatory actions and prepared various submissions, as well as a Scientist position focusing on analytical method development and compliance with regulatory standards. Anusha began a career in quality control as an Analytical Chemist at Dr. Reddy's Laboratories. Anusha holds an Associate’s Degree in Regulatory Affairs Certification from RAPS and a Bachelor's Degree in Pharmacy from Vaagdevi College of Engineering.
Chartwell Pharmaceuticals
CHARTING A COURSE TO WELLNESS Chartwell Pharmaceuticals is a US-based development, manufacturing and commercial organization located in Congers, New York. Our facility produces prescription pharmaceutical products with a commitment to superior quality, compliance, and customer service. Chartwell Pharmaceuticals has a long history as a preferred manufacturing partner for prescription solid dosage products in tablet, capsule, and powders forms. Recent expansion now adds capabilities for suspensions, enemas and liquids manufacturing - including Unit Dose cups. Our rooms are large, our ceilings are high, and facilities are pristine. Our exceptional hands-on leadership team and technical staff bring decades of pharmaceutical industry experience in manufacturing and analytical services for development, scale-up, transferring, changing, launching, and supplying products. Under our own Chartwell labels, our mission is to provide a consistent, timely and quality product supply to our pharmacy customers and their patients. Our current portfolio stands at over 250 Orange Book listed ANDAs and NDAs, with an aggressive asset development and acquisition program in place. Supported by Chartwell Labs, our Formulations and Analytical team, we are quickly continuing to broaden our line through commercial Chartwell-labeled branding. Chartwell Pharmaceuticals is proud to be manufacturing "Made in the USA" products.